Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL UDDER HEALTH MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL UDDER HEALTH MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL UDDER HEALTH MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES MODEL
4.3 COMPETITIVE INTELLIGENCE
5. INDUSTRY INSIGHTS
5.1 PATENT ANALYSIS
5.1.1 PATENT LANDSCAPE
5.1.2 USPTO NUMBER
5.1.3 PATENT EXPIRY
5.1.4 EPIO NUMBER
5.1.5 PATENT STRENGTH AND QUALITY
5.1.6 PATENT CLAIMS
5.1.7 PATENT CITATIONS
5.1.8 PATENT LITIGATION AND LICENSING
5.1.9 FILE OF PATENT
5.1.10 PATENT RECEIVED CONTRIES
5.1.11 TECHNOLOGY BACKGROUND
5.2 DRUG TREATMENT RATE BY MATURED MARKETS
5.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
5.4 PATIENT FLOW DIAGRAM
5.5 KEY PRICING STRATEGIES
5.6 KEY PATIENT ENROLLMENT STRATEGIES
5.7 INTERVIEWS WITH SPECIALIST
5.8 OTHER KOL SNAPSHOTS
6. EPIDEMIOLOGY
6.1 INCIDENCE OF ALL BY GENDER
6.2 TREATMENT RATE
6.3 MORTALITY RATE
6.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
6.5 PATIENT TREATMENT SUCCESS RATES
7. MERGERS AND ACQUISITION
7.1 LICENSING
7.2 COMMERCIALIZATION AGREEMENTS
8. REGULATORY FRAMEWORK
8.1 REGULATORY APPROVAL PROCESS
8.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
8.3 REGULATORY APPROVAL PATHWAYS
8.4 LICENSING AND REGISTRATION
8.5 POST-MARKETING SURVEILLANCE
8.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
9. PIPELINE ANALYSIS
9.1 CLINICAL TRIALS AND PHASE ANALYSIS
9.2 DRUG THERAPY PIPELINE
9.3 PHASE III CANDIDATES
9.4 PHASE II CANDIDATES
9.5 PHASE I CANDIDATES
9.6 OTHERS (PRE-CLINICAL AND RESEARCH)
10. MARKETED DRUG ANALYSIS
10.1 DRUG
10.1.1 BRAND NAME
10.1.2 GENERICS NAME
10.2 THERAPEUTIC INDIACTION
10.3 PHARACOLOGICAL CLASS OD THE DRUG
10.4 DRUG PRIMARY INDICATION
10.5 MARKET STATUS
10.6 MEDICATION TYPE
10.7 DRUG DOSAGES FORM
10.8 DOSAGES AVAILABILITY
10.9 PACKAGING TYPE
10.10 DRUG ROUTE OF ADMINISTRATION
10.11 DOSING FREQUENCY
10.12 DRUG INSIGHT
10.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
10.13.1 FORECAST MARKET OUTLOOK
10.13.2 CROSS COMPETITION
10.13.3 THERAPEUTIC PORTFOLIO
10.13.4 CURRENT DEVELOPMENT SCENARIO
11. MARKET ACCESS
11.1 10-YEAR MARKET FORECAST
11.2 CLINICAL TRIAL RECENT UPDATES
11.3 ANNUAL NEW FDA APPROVED DRUGS
11.4 DRUGS MANUFACTURER AND DEALS
11.5 MAJOR DRUG UPTAKE
11.6 CURRENT TREATMENT PRACTICES
11.7 IMPACT OF UPCOMING THERAPY
12. R & D ANALYSIS
12.1 COMPARATIVE ANALYSIS
12.2 DRUG DEVELOPMENTAL LANDSCAPE
12.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
12.4 THERAPEUTIC ASSESSMENT
12.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
13. MARKET OVERVIEW
13.1 DRIVERS
13.2 RESTRAINTS
13.3 OPPORTUNITIES
13.4 CHALLENGES
14. GLOBAL UDDER HEALTH MARKET , BY PRODUCT
14.1 OVERVIEW
14.2 DEVICES
14.2.1 MILK MANAGEMENT SYSTEM
14.2.2 MILK SAMPLING EQUIPMENT
14.2.3 MILK QUALITY ANALYZER
14.3 PHARMACEUTICALS
14.3.1 BY DRUG TYPE
14.3.1.1. ANTIBIOTIC
14.3.1.1.1. CEPRAVIN DC
14.3.1.1.2. COBACTAN RANGE
14.3.1.1.3. MASTIPLAN LC
14.3.1.2. VACCINES(OXYTOCIN)
14.3.1.3. ANTI-INFLAMMATORY
14.3.1.3.1. FLUNIXIN MEGLUMINE
14.3.1.3.2. KETOPROFEN
14.3.1.3.3. CHLORHEXIDINE
14.3.1.3.4. CLOXACILLIN
14.3.1.4. INTRAMAMMERY INFUSION
14.3.2 BY DRUG FORM
14.3.2.1. BRANDED
14.3.2.2. GENERIC
14.3.3 BY ROUTE OF ADMINISTRATION
14.3.3.1. INJECTABLE
14.3.3.2. ORAL
14.3.3.3. TOPICAL
14.3.4 BY MODE OF PRESCRIPTION
14.3.4.1. PRESCRIPTION
14.3.4.2. OVER-THE-COUNTER
14.3.5 OTHER
14.4 SUPPLEMENTS
14.4.1 NUTRITIONAL SUPPLEMENTS
14.4.1.1. MINERAL
14.4.1.1.1. CALCIUM
14.4.1.1.2. MAGNESIUM
14.4.1.1.3. PHOSPHORUS
14.4.1.1.4. SODIUM AND POTASSIUM
14.4.1.2. VITAMIN
14.4.1.3. FATTY ACIDS & OMEGA-3S
14.4.2 PROBIOTICS & PREBIOTICS
14.4.3 IMMUNE SYSTEM BOOSTERS
14.4.3.1. BETA-GLUCANS
14.4.3.2. YEAST-BASED SUPPLEMENTS
14.4.4 HERBAL & BOTANICAL
14.4.5 ANTI-INFLAMMATORY
14.4.5.1. CURCUMIN
14.4.5.2. OMEGA-3 FATTY ACIDS
15. GLOBAL UDDER HEALTH MARKET , BY ANIMAL TYPE
15.1 OVERVIEW
15.2 DAIRY CATTLE
15.3 SHEEP
15.4 GOATS
15.5 SHEEP
15.6 BUFFALOES
15.7 YAKS
15.8 CAMELS
15.9 OTHERS
16. GLOBAL UDDER HEALTH MARKET, BY END USER
16.1 OVERVIEW
16.2 DAIRY FARMERS
16.3 VETERINARIANS AND ANIMAL CARE PROVIDERS
16.4 RESEARCH INSTITUTIONS
16.5 HOMECARE
16.6 OTHERS
17. GLOBAL UDDER HEALTH MARKET , BY DISTRIBUTION CHANNEL
17.1 OVERVIEW
17.2 DIRECT TENDER
17.3 RETAIL SALES
17.3.1 OFFLINE
17.3.2 ONLINE
17.4 OTHERS
18. GLOBAL UDDER HEALTH MARKET , COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: GLOBAL
18.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
18.3 COMPANY SHARE ANALYSIS: EUROPE
18.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
18.5 MERGERS & ACQUISITIONS
18.6 NEW PRODUCT DEVELOPMENT & APPROVALS
18.7 EXPANSIONS
18.8 REGULATORY CHANGES
18.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
19. GLOBAL UDDER HEALTH MARKET , BY GEOGRAPHY
19.1 GLOBAL UDDER HEALTH MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1.1 NORTH AMERICA
19.1.1.1. U.S.
19.1.1.1.1. U.S. UDDER HEALTH TREATMENT MARKET, BY PRODUCT
19.1.1.1.2. U.S. UDDER HEALTH TREATMENT MARKET, BY ANIMAL TYPE
19.1.1.1.3. U.S. UDDER HEALTH TREATMENT MARKET, BY END USER
19.1.1.1.4. U.S. UDDER HEALTH TREATMENT MARKET, BY DISTRIBUTION CHANNEL
19.1.2 CANADA
19.1.3 MEXICO
19.2 EUROPE
19.2.1 GERMANY
19.2.2 FRANCE
19.2.3 U.K.
19.2.4 ITALY
19.2.5 SPAIN
19.2.6 RUSSIA
19.2.7 TURKEY
19.2.8 NETHERLANDS
19.2.9 SWITZERLAND
19.2.10 AUSTRIA
19.2.11 IRELAND
19.2.12 NORWAY
19.2.13 POLAND
19.2.14 REST OF EUROPE
19.3 ASIA-PACIFIC
19.3.1 JAPAN
19.3.2 CHINA
19.3.3 TAIWAN
19.3.4 SOUTH KOREA
19.3.5 INDIA
19.3.6 AUSTRALIA
19.3.7 SINGAPORE
19.3.8 THAILAND
19.3.9 MALAYSIA
19.3.10 INDONESIA
19.3.11 PHILIPPINES
19.3.12 VIETNAM
19.3.13 REST OF ASIA-PACIFIC
19.4 SOUTH AMERICA
19.4.1 BRAZIL
19.4.2 ARGENTINA
19.4.3 CHILE
19.4.4 PERU
19.4.5 REST OF SOUTH AMERICA
19.5 MIDDLE EAST AND AFRICA
19.5.1 SOUTH AFRICA
19.5.2 SAUDI ARABIA
19.5.3 UAE
19.5.4 EGYPT
19.5.5 KUWAIT
19.5.6 ISRAEL
19.5.7 REST OF MIDDLE EAST AND AFRICA
19.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20. GLOBAL UDDER HEALTH MARKET , SWOT AND DBMR ANALYSIS
21. GLOBAL UDDER HEALTH MARKET , COMPANY PROFILE
21.1 MERCK & CO., INC.
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 ZOETIS INC.
21.3 BOEHRINGER INGELHEIM GMBH
21.4 ELANCO ANIMAL HEALTH INCORPORATED
21.5 CEVA SANTÉ ANIMALE
21.6 VETOQUINOL SA
21.7 FRVIRBAC SA
21.8 ECOLAB INC.
21.9 GEA GROUP AKTIENGESELLSCHAFT
21.10 DELAVAL INTERNATIONAL AB
21.11 BOUMATIC LLC
21.12 ORFFA INTERNATIONAL HOLDING BV
21.13 LELY INTERNATIONAL NV
21.14 AHV INTERNATIONAL BV
21.15 ALBERT KERBL GMBH
21.16 G. SHEPHERD ANIMAL HEALTH LIMITED
21.17 AMBIG EQUIPMENT LIMITED
21.18 DRAMINSKI SA
21.19 ZENEX ANIMAL HEALTH INDIA PRIVATE LIMITED
21.20 BLACKMANGO HERB
21.21 NICOSIA BIOLABS INTERNATIONAL PRIVATE LIMITED
21.22 RING BIOTECHNOLOGY CO., LTD.
21.23 KORU DIAGNOSTICS LTD.
21.24 MASTAPLEX LIMITED
21.25 AR BROWN CO., LTD.
21.25.1 COMPANY OVERVIEW
21.25.2 REVENUE ANALYSIS
21.25.3 GEOGRAPHIC PRESENCE
21.25.4 PRODUCT PORTFOLIO
21.25.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
22. RELATED REPORTS
23. CONCLUSION
24. QUESTIONNAIRE
25. ABOUT DATA BRIDGE MARKET RESEARCH
